

# RSC Advances

Supporting Information (SI)

## Antimicrobial Properties and Biocompatibility of semi-synthetic Carbohydrate-based Ionic Hydrogels

Sina Lambrecht<sup>a</sup>, Alina Gazizova<sup>b</sup>, Selin Kara<sup>c,d</sup>, Johanna Meyer<sup>c,\*</sup>, Stefan Jopp<sup>a,\*</sup>

<sup>a</sup> Department of Life, Light and Matter, University of Rostock, Albert-Einstein-Str. 25, 18059, Rostock, Germany.

<sup>b</sup> Institute of Chemistry, University of Rostock, Albert-Einstein-Str. 3a, 18059, Rostock, Germany.

<sup>c</sup> Institute of Technical Chemistry, Leibniz University Hannover, Callinstraße 5, 30167 Hannover, Germany.

<sup>d</sup> Biocatalysis and Bioprocessing Group, Department of Biological and Chemical Engineering, Aarhus University, Gustav Wieds Vej 10, 8000 Aarhus, Denmark.

**E-mails:** johanna.meyer@iftc.uni-hannover.de, stefan.jopp@uni-rostock.de

## Table of Contents

1	Synthetic procedures and analytical data	S3
1.1	NMR Spectra	S4
1.2	IR Spectra	S6
1.3	Hydrogel composition	S7
2	Antimicrobial Activity – Disk Diffusion Method	S8
3	Cell viability of L929 cells – CellTiter blue (CTB) viability assay	S11
3.1	Eluate tests	S11
3.2	Direct contact tests	S12
4	Microscopic analysis – Microscopic images of L929 cells	S13
4.1	Eluate tests	S13
4.2	Direct contact tests	S15
5	Cell staining (live/dead) assay – Calcein-AM/PI staining	S16
5.1	Eluate tests	S16
5.2	Direct contact tests	S19
6	LC-MS data	S20

## 1. Synthetic procedures and analytical data

**Synthetic procedure for the synthesis of Methyl-6-iodo- $\alpha$ -D-glucopyranoside (1).** Methyl- $\alpha$ -D-glucopyranoside (10 mmol), triphenylphosphine (15.5 mmol), iodine (14.5 mmol), and imidazole (20 mmol) were refluxed in THF (60 mL) for 4 h. The resulting solid was filtered off, the solvent was removed and the product (91 % yield) was obtained after column chromatography (CHCl<sub>3</sub>/MeOH 12:1). <sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>):  $\delta$  = 2.87–2.95 (m, 1H); 3.16–3.27 (m, 3H); 3.31 (s, 3H, CH<sub>3</sub>); 3.34–3.42 (m, 1H); 3.50–3.57 (m, 1H); 4.54 (d, 1H, <sup>3</sup>J = 3.65 Hz, H-1); 4.78 (d, 1H, <sup>3</sup>J = 6.43 Hz, OH); 4.86 (d, 1H, <sup>3</sup>J = 4.99 Hz, OH); 5.17 (d, 1H, <sup>3</sup>J = 5.83 Hz, OH). <sup>13</sup>C-NMR (75 MHz, DMSO-d<sub>6</sub>):  $\delta$  = 9.5 (C-6); 54.6 (CH<sub>3</sub>); 70.9, 71.9, 72.7, 74.1 (C-2, C-3, C-4, C-5); 99.8 (C-1).

**Synthetic procedure for the quaternization with imidazoles to 1-(Methyl- $\alpha$ -D-glucopyranosid-6-yl)-3-vinylimidazolium iodide (GVIM-I) (2).** Methyl-6-iodo- $\alpha$ -D-glucopyranoside (3 mmol) and the *N*-vinylimidazole (5 mmol) were dissolved in DMF (5 mL) and stirred at 95 °C for 24 hours. After cooling down, ethyl acetate (40 mL) was added and the flask was stored in a fridge overnight. The solvent was decanted and the precipitated solid was repeatedly washed with ethyl acetate and dried under a high vacuum to achieve the product, yielding in a light-brown solid (73 % yield). <sup>1</sup>H-NMR (250 MHz, D<sub>2</sub>O):  $\delta$  = 3.25 (s, 3 H, OCH<sub>3</sub>); 3.24–3.28 (m, 1H, H-4); 3.58 (dd, 1H, <sup>3</sup>J = 9.77 Hz, <sup>3</sup>J = 3.77 Hz, H-2); 3.66–3.75 (m, 1H, H-3); 3.95 (ddd, 1H, <sup>3</sup>J = 9.96 Hz, <sup>3</sup>J = 7.47 Hz, <sup>3</sup>J = 2.46 Hz, H-5); 4.50 (dd, 1H, <sup>2</sup>J = 14.55 Hz, <sup>3</sup>J = 7.38 Hz, H-6a); 4.70 (dd, 1H, <sup>2</sup>J = 14.55 Hz, <sup>3</sup>J = 2.55 Hz, H-6b); 4.85 (d, 1H, <sup>3</sup>J = 3.77 Hz, H-1); 5.49 (dd, 1H, <sup>3</sup>J = 8.68 Hz, <sup>2</sup>J = 2.84 Hz, Vinyl-CH<sub>2</sub>); 5.86 (dd, 1H, <sup>3</sup>J = 15.58 Hz, <sup>2</sup>J = , Vinyl-CH<sub>2</sub>); 7.2 (dd, 1H, <sup>3</sup>J = 15.58 Hz, <sup>3</sup>J = 8.70 Hz, Vinyl-CH); 7.70 (d, 1H, <sup>3</sup>J = 2.09 Hz, H<sub>Ar</sub>); 7.86 (d, 1H, <sup>3</sup>J = 2.11 Hz, H<sub>Ar</sub>); 9.16 (s, 1H, H<sub>Ar</sub>). <sup>13</sup>C-NMR (125 MHz, D<sub>2</sub>O):  $\delta$  = 50.2 (C-6); 55.1 (OCH<sub>3</sub>); 69.2 (C-5); 70.5 (C-4); 71.0 (C-2); 72.8 (C-3); 99.3 (C-1); 109.8 (Vinyl-CH<sub>2</sub>); 119.4, 123.8 (CH<sub>Ar</sub>); 123.8 (Vinyl-CH); 135.0 (CH<sub>Ar</sub>).

## 1.1 NMR Spectra




Figure S1. <sup>1</sup>H-NMR (DMSO) spectrum of compound Methyl-6-iodo- $\alpha$ -D-glucopyranoside **1**.






Figure S2. <sup>13</sup>C-NMR (DMSO) spectrum of compound Methyl-6-iodo- $\alpha$ -D-glucopyranoside **1**.




**Figure S3.**  $^1\text{H-NMR}$  ( $\text{D}_2\text{O}$ ) spectrum of compound 1-(Methyl- $\alpha$ -D-glucopyranosid-6-yl)-3-vinylimidazolium iodide (GVIM-I) 2.




**Figure S4.**  $^{13}\text{C-NMR}$  ( $\text{D}_2\text{O}$ ) spectrum of compound 1-(Methyl- $\alpha$ -D-glucopyranosid-6-yl)-3-vinylimidazolium iodide (GVIM-I) 2.

## 1.2 ATR-IR spectra



**Figure S5.** ATR-FTIR spectrum of compound 1.



**Figure S6.** ATR-FTIR spectrum of compound 2.

## 1.2 Weighing scales for hydrogel production

**Table S1.** Weighing-in scale for the production of hydrogels with LAP as initiator, according to i).


	GVIM-I		PBS	Crosslinker		LAP	
	c [mol/l]	m [mg]	V [ $\mu$ l]	c [mol%]	V [ $\mu$ l]	c [w%]	m [mg]
<b>EGDA</b>	1.25	100	200	10	3.9	3.1	9.4
<b>PEGDA 250</b>	1.25	100	200	10	5.7	2.0	6.1
<b>PEGDA 700</b>	1.25	100	200	10	15.7	0.5	1.6
<b>MBAA</b>	1.25	100	200	10	3.9	1.0	3.0
<b>PEGDA 575</b>	1.25	100	200	10	12.9	0.5	1.6

**Table S2.** Weighing-in scale for the production of hydrogels with APS/TEMED as initiator, according to ii).

	GVIM-I		PBS	Crosslinker		APS/TEMED		
	c [mol/l]	m [mg]	V [ $\mu$ l]	c [mol%]	V [ $\mu$ l]	C <sub>total</sub> [W%]	V <sub>APS</sub> [ $\mu$ l]	V <sub>TEMED</sub> [ $\mu$ l]
<b>MBAA</b>	1.25	100	172.1	13.0	5.0	10.7	27.9 <sup>a</sup>	27.9
<b>PEGDA 575</b>	1.25	100	162.5	10.4	13.4	6.8	37.5 <sup>b</sup>	18.0


Note to APS solution: a) 400 mg in 1 ml PBS and b) 200 mg in 1 ml PBS.

## 2. Antimicrobial Activity – Disk Diffusion Method




**Figure S7.** Overview of the disk diffusion tests against *B. subtilis* (P positive control Gentamicin; N negative control LB medium; 1 EGDA; 2 P250; 3 P575 10%; 4 P575 15%; 5 P575 20%; 6 P700; 7 MBAA LAP; 8 MBAA A/T; 9 P575 A/T).






**Figure S8.** Overview of the disk diffusion tests against *E. coli* (P positive control Gentamicin; N negative control LB medium; 1 EGDA; 2 P250; 3 P575 10%; 4 P575 15%; 5 P575 20%; 6 P700; 7 MBAA LAP; 8 MBAA A/T; 9 P575 A/T).




**Figure S9.** Overview of the disk diffusion tests against *C. auris* (P positive control Amphotericin B; N negative control LB medium (+ 2% glucose)); 1 EGDA; 2 P250; 3 P575 10%; 4 P575 15%; 5 P575 20%; 6 P700; 7 MBAA LAP; 8 MBAA A/T; 9 P575 A/T).

### 3. Cell viability of L929 cells - CellTiter blue (CTB) viability assay

#### 3.1. Eluate tests




**Figure S10.** CTB of different hydrogel eluate samples: A EGDA; B P250; C P575 10%; D P575 15%; E P575 20%; F P700.



**Figure S11.** CTB of different hydrogel eluate samples: A MBAA; B MBAA A/T; C P575 AT.

### 3.2. Direct Contact tests




**Figure S12.** CTB of all 3 biological replicates of different treated hydrogels with 1 no treatment, 2 washing in DMEM 72 h, 3 washing in DMEM 3x24 h, 4 washing in EtOH (70%) 24 h and in DMEM 2x24 h, 5 UV irradiation 1 h, 6 UV irradiation 1 h and washing in DMEM 3x24 h, 7 UV irradiation 1 h, washing in EtOH (70%) and in DMEM 3x24 h.




#### 4. Microscopic images of L929 cells

##### 4.1. Eluate tests




**Figure S13.** Microscopic brightfield images of L929 cells after 0 h and 48 h in different concentrated (100%, 10%, 1%, and 0.1%) hydrogel eluates (EGDA, PEGDA 250, PEGDA 575 10%, PEGDA 575 15%, and PEGDA 20%). Scale bar 400 μm.



**Figure S14.** Microscopic brightfield images of L929 cells after 0 h and 48 h in different concentrated (100%, 10%, 1%, and 0.1%) hydrogel eluates (PEGDA 700, MBAA, MBAA A/T, and PEGDA 575 A/T). Scale bar 400 μm.




## 4.2. Direct contact tests



**Figure S15.** Microscopic brightfield images of L929 cells after 0 h and 48 h contact with different treated hydrogels with **1** no treatment, **2** washing in DMEM 72 h, **3** washing in DMEM 3x24 h, **4** washing in EtOH (70%) 24 h and in DMEM 2x24 h, **5** UV irradiation 1 h, **6** UV irradiation 1 h and washing in DMEM 3x24 h, **7** UV irradiation 1 h, washing in EtOH (70%) and in DMEM 3x24 h.


## 5. Cell staining (live/dead assay) - Calcein-AM/PI staining

### 5.1. Eluate tests




**Figure S16.** Calcein-AM/PI staining of L929 cell cultivated for 48 h in different concentrated (100%, 10%, 1% and 0.1%) hydrogel eluates from EGDA, PEGDA 250, PEGDA 575 10% and PEGDA 575 15% prepared with LAP (scale bar 400  $\mu\text{m}$ ).






**Figure S17.** Calcein-AM/PI staining of L929 cell cultivated for 48 h in different concentrated (100%, 10%, 1% and 0.1%) hydrogel eluates from PEGDA 575 20% and PEGDA 700 and MBAA prepared with LAP and MBAA prepared with APT/TEMED (scale bar 400  $\mu$ m).



**Figure S18** Calcein-AM/PI staining of L929 cell cultivated for 48 h in different concentrated (100%, 10%, 1% and 0.1%) hydrogel eluates from PEGDA 575 prepared with APT/TEMED (scale bar 400  $\mu\text{m}$ ).




## 5.2. Direct contact tests




**Figure S19.** Calcein-AM/PI staining of L929 cell cultivated for 48 h in contact with different treated hydrogels with **1** no treatment, **2** washing in DMEM 72 h, **3** washing in DMEM 3x24 h, **4** washing in EtOH (70%) 24 h and in DMEM 2x24 h, **5** UV irradiation 1 h, **6** UV irradiation 1 h and washing in DMEM 3x24 h, **7** UV irradiation 1 h, washing in EtOH (70%) and in DMEM 3x24 h. For each sample, a picture is shown with and without hydrogel (scale bar 400  $\mu$ m).


## 6. LC-MS



**Figure S20.** Calibration of GVIM-I via LC-MSMS.



**Figure S21.** **A** Chromatogram of pure GVIM-I in negative scan mode, **B** Mass spectrum corresponding to **A**, **C** Chromatogram of pure GVIM-I in positive scan mode and **D** Mass spectrum corresponding to **C**.



**Figure S22.** **A** Chromatogram of sample B1 48 h in positive scan mode (MS), **B** mass spectra (MS) of sample B1 48 h corresponding to **A**, **C** Chromatogram of sample B1 48 h in positive scan mode (MSMS) and **D** mass spectra (MSMS) of sample B1 48 h corresponding to **C**.